Cargando…

Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study

OBJECTIVE: Secukinumab improved the signs and symptoms of ankylosing spondylitis (AS) over 52 weeks in the phase III MEASURE 2 study. Here, we report longer‐term (104 weeks) efficacy and safety results. METHODS: Patients with active AS were randomized to subcutaneous secukinumab 150 mg, 75 mg, or pl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marzo‐Ortega, H., Sieper, J., Kivitz, A., Blanco, R., Cohen, M., Martin, R., Readie, A., Richards, H. B., Porter, B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Spondyloarthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518281/ https://www.ncbi.nlm.nih.gov/pubmed/28235249 http://dx.doi.org/10.1002/acr.23233

Ejemplares similares

Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2
por: Marzo-Ortega, Helena, et al.
Publicado: (2017)

Effect of Secukinumab on Patient‐Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1)
por: Deodhar, Atul A., et al.
Publicado: (2016)

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
por: Braun, Jürgen, et al.
Publicado: (2018)

Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study
por: Baraliakos, Xenofon, et al.
Publicado: (2019)

Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study
por: Deodhar, Atul, et al.
Publicado: (2020)

Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis
por: Braun, Juergen, et al.
Publicado: (2023)

Changes in ankylosing spondylitis incidence, prevalence and time to diagnosis over two decades
por: Crossfield, Samantha S R, et al.
Publicado: (2021)

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
por: Schreiber, Stefan, et al.
Publicado: (2019)

Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction
por: Baraliakos, X, et al.
Publicado: (2016)

Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study
por: Webers, Casper, et al.
Publicado: (2018)

Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis
por: Li, Zhixiu, et al.
Publicado: (2021)

Characterising the axial phenotype of psoriatic arthritis: a study comparing axial psoriatic arthritis and ankylosing spondylitis with psoriasis from the REGISPONSER registry
por: Michelena, Xabier, et al.
Publicado: (2022)

Functional Genomic Analysis of a RUNX3 Polymorphism Associated With Ankylosing Spondylitis
por: Vecellio, Matteo, et al.
Publicado: (2021)

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
por: Deodhar, Atul, et al.
Publicado: (2021)

Evidence for a second ankylosing spondylitis-associated RUNX3 regulatory polymorphism
por: Vecellio, Matteo, et al.
Publicado: (2018)

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
por: van der Heijde, Désirée, et al.
Publicado: (2022)

Relationship between the gut and the spine: a pilot study of first-degree relatives of patients with ankylosing spondylitis
por: Kehl, Amy S, et al.
Publicado: (2017)

Clinical and genetic factors associated with radiographic damage in patients with ankylosing spondylitis
por: Nam, Bora, et al.
Publicado: (2023)

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension
por: van der Heijde, Désirée, et al.
Publicado: (2022)

Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison
por: Braun, J., et al.
Publicado: (2019)

Ankylosing spondylitis and mortality following hospitalised pneumonia: a population-based cohort study
por: Holland-Fischer, Mette, et al.
Publicado: (2020)

Social Role Participation Questionnaire for patients with ankylosing spondylitis: translation into Dutch, reliability and construct validity
por: van Genderen, Simon, et al.
Publicado: (2016)

Trends in treatment and outcomes of ankylosing spondylitis in outpatient rheumatological care in Germany between 2000 and 2012
por: Huscher, Dörte, et al.
Publicado: (2015)

Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension
por: Deodhar, Atul, et al.
Publicado: (2021)

Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial
por: Sieper, J, et al.
Publicado: (2015)

Cardiac conduction disturbances in patients with ankylosing spondylitis: results from a 5-year follow-up cohort study
por: Bengtsson, Karin, et al.
Publicado: (2019)

Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3
por: Pavelka, Karel, et al.
Publicado: (2017)

Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
por: van der Heijde, Désirée, et al.
Publicado: (2020)

Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis
por: Maneiro, Jose Ramon, et al.
Publicado: (2015)

Non-classical human leucocyte antigens in ankylosing spondylitis: possible association with HLA-E and HLA-F
por: Santos, Margarida Rodrigues, et al.
Publicado: (2018)

Do patients with ankylosing spondylitis adapt to their disease? Evidence from a ‘then-test’ in patients treated with TNF inhibitors
por: Essers, Ivette, et al.
Publicado: (2015)

Association of childhood infections and perinatal factors with ankylosing spondylitis: a Swedish nationwide case–control and sibling study
por: Morin, Matilda, et al.
Publicado: (2023)

Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 MEASURE 3 Study
por: Pavelka, Karel, et al.
Publicado: (2020)

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
por: Rudwaleit, M., et al.
Publicado: (2016)

Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis
por: Ramiro, Sofia, et al.
Publicado: (2015)

Employment and the role of personal factors among patients with ankylosing spondylitis: a Dutch cross-sectional case-control study
por: Webers, Casper, et al.
Publicado: (2018)

Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials
por: McInnes, Iain B, et al.
Publicado: (2022)

Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial
por: Navarro-Compán, Victoria, et al.
Publicado: (2022)

Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis
por: Derakhshan, Mohammad H, et al.
Publicado: (2020)

Does body mass index (BMI) influence the Ankylosing Spondylitis Disease Activity Score in axial spondyloarthritis?: Data from the SPACE cohort
por: Rubio Vargas, Roxana, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_k9jhv3ssj5e0l7vqd3p9evoold